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Key Points 
1. USP7 is overexpressed and regulates homologous recombination repair in CLL cells. 
2. USP7 inhibition is selectively cytotoxic to CLL cells independently of ATM and p53, 
and synergizes with chemotherapy. 
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Abstract 
The role of the deubiquitylase ubiquitin-specific protease 7 (USP7) in the regulation of the 
p53-dependent DNA damage response (DDR) pathway is well established. Whilst previous 
studies have mostly focused on the mechanisms underlying how USP7 directly controls p53 
stability, we have recently shown that USP7 modulates the stability of the DNA damage 
responsive E3 ubiquitin ligase, RAD18. This suggests that targeting USP7 may have 
therapeutic potential even in tumors with defective p53 or ibrutinib-resistance. To test this 
hypothesis, we studied the effect of USP7 inhibition in chronic lymphocytic leukemia (CLL) 
where the ataxia telangiectasia mutated (ATM)-p53 pathway is inactivated with relatively 
high frequency, leading to treatment resistance and poor clinical outcome. We demonstrate 
that USP7 is upregulated in CLL cells and its loss or inhibition disrupts homologous 
recombination repair (HRR). Consequently, USP7 inhibition induces significant tumor cell 
killing independent of ATM and p53 through the accumulation of genotoxic levels of DNA 
damage. Moreover, USP7 inhibition sensitizes p53-defective, chemoresistant CLL cells to 
clinically achievable doses of HRR-inducing chemotherapeutic agents in vitro and in vivo in a 
murine xenograft model. Together, these results identify USP7 as a promising therapeutic 
target for the treatment of hematological malignancies with DDR defects, where ATM/p53-
dependent apoptosis is compromised. 
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Introduction 
The clinical heterogeneity of CLL is underscored by genomic aberrations, particularly those 
involving the chromosomal regions 17p and 11q. These are the sites of the DDR genes ATM 
and TP53 respectively, deletions or mutations of which can adversely affect prognosis and 
treatment response.1-4 ATM and p53 play essential roles in DDR by coordinating DNA repair 
with apoptosis. Defects in DDR genes facilitate cellular transformation and/or tumor 
progression by allowing mutations and chromosomal alterations to persist and accumulate, 
thus increasing genomic instability.5 DDR defects also result in resistance to conventional 
chemotherapeutic agents. This has prompted the development of DDR-independent 
therapies including monoclonal antibodies, as well as Bcl-2 and B-cell receptor (BCR) 
signaling inhibitors.6-10 Although these agents act independently of the ATM/p53 pathway, in 
vitro studies have shown that CLL cells harboring del(17p) or TP53 mutations are less 
sensitive to the BCR signaling inhibitor, ibrutinib.11 Moreover, BCR signaling inhibitors are 
not curative, and patients with del(17p) CLL continue to exhibit inferior clinical outcomes with 
these agents, indicating that alternative treatment strategies and therapeutic combinations 
are still needed.6,10,12 
DDR-deficient cells rely on co-operating DNA repair pathways for survival. Therefore, an 
alternative therapeutic approach involves the selective targeting of DDR-deficient CLL cells 
by inhibiting these pathways, which results in synthetic lethality.13,14 Recently, we have 
shown that poly ADP-ribose polymerase 1 (PARP1) inhibition selectively targeted the HRR 
deficiency in ATM-deficient CLL, and that ataxia telangiectasia and Rad3-related (ATR) 
inhibition could be used to exploit the replication checkpoint deficiency in ATM- or TP53-
deficient CLL.15,16 Both approaches resulted in CLL cell death by mitotic catastrophe. Unlike 
DDR-independent therapies, such strategies specifically target the more genomically 
unstable and aggressive DDR-deficient tumor subpopulations. 
AGATHANGGELOU et al USP7 INHIBITION TARGETS ATM AND P53 MUTANT CLL 
6 
 
Protein ubiquitylation is an essential post-translational modification for regulating cellular 
DDR.17 It is critical for controlling the stability of many DDR proteins and in regulating their 
function and subcellular localization. Ubiquitylation involves the covalent attachment of 
ubiquitin residues onto target proteins through the sequential actions of E1, E2 and E3 
enzymes, which activate, conjugate and ligate ubiquitin, respectively. Conversely, 
deubiquitylases (DUBs) are enzymes that remove ubiquitin residues.17 USP7 is a DUB that 
plays a major role in regulating p53 function through its ability to stabilize MDM2, an E3-
ubiquitin ligase that ubiquitylates and targets p53 for proteasomal degradation.18-20  Genetic 
studies have demonstrated that loss of USP7 allows MDM2 auto-ubiquitylation and 
subsequent degradation, which results in p53 stabilization and induction of G1 cell cycle 
arrest or apoptosis.21 
Consistent with this role, pharmacological targeting of USP7 has been shown to reverse 
MDM2-mediated downregulation of p53 leading to enhanced cytotoxicity of multiple 
myeloma cells.22 Alternatively, p53 can be stabilized by MDM2 inhibitors such as nutlins, but, 
unlike USP7 inhibition, their efficacy appears to be entirely p53-dependent and therefore of 
limited utility in p53-deficient malignancies.23,24 This difference may be a reflection of the 
increasing number of p53-independent roles identified for USP7.25-28 Indeed, we recently 
showed that the loss of USP7 destabilizes RAD18, an E3-ubiquitin ligase, compromising 
post-replication repair.29 
In view of this, we reasoned that USP7 could represent an attractive therapeutic target for 
tumors containing ATM or p53 functional defects. Using CLL as a tumor model with a high 
frequency of ATM/TP53 aberrations, we demonstrate that inhibition of USP7 leads to 
selective loss of CLL viability independent of ATM and p53 function, mediated through the 
accumulation of unrepaired DNA double strand breaks (DSBs). Furthermore, we show, for 
the first time, that USP7 inhibition compromises HRR and thus sensitizes tumor cells to 
HRR-inducing chemotherapeutic agents in vitro and in vivo. 
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Materials and methods 
Patient samples and cell lines 
Peripheral blood mononuclear cells (PBMCs) were isolated from CLL samples collected from 
patients across Birmingham, UK and healthy volunteers. This study was approved by the 
South Birmingham Ethics Committee, performed according to institutional guidelines, and 
written consent was obtained from all participants. The 80 CLL samples all contained >90% 
CD19+ CD5+ cells. Analysis of IGHV, ATM and TP53 genes, and ATM/p53 function, was 
performed as described previously (supplemental Table S1; see the Supplemental Data 
file).30,31 All primary CLL samples and isogenic CLL cell lines (CII, PGA and Mec1 
expressing short hairpin RNAs complementary to either green fluorescent protein (GFP) or 
ATM) were cultured in RPMI 1640 (Thermo Fisher Scientific, Rugby, UK) supplemented with 
10% fetal bovine serum (FBS; Thermo Fisher Scientific). HeLa and U2OS cells were grown 
in Dulbecco’s modified Eagle’s medium/10% FBS. Primary CLL cells and healthy donor 
PBMCs were induced to proliferate by co-culturing with mouse embryonic fibroblasts 
expressing CD40 ligand (CD40L), supplemented with 25ng/mL IL-21 (Thermo Fisher 
Scientific).32 
 
Immunoblotting 
Protein lysates were immunoblotted as previously described30,31 using antibodies described 
in supplemental data.  
 
Xenotransplantation and treatment 
Animals were treated in accordance with United Kingdom Home Office guidelines and thus 
the experimental endpoint was at the first sign of illness exceeding licence restrictions in any 
treatment arm. Six week old NOD/LtSz-SCID/IL2tm1Wjl/SzJ (NSG) mice were sublethally 
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irradiated (1.25Gy) prior to intravenous (tail vein) injection of Mec1 cells (3x106). Intravenous 
bi-weekly treatment with DMSO, HBX19818 (5mg/kg or 10mg/kg), cyclophosphamide 
(20mg/kg; Baxter, Newbury, UK), rituximab (Roche, West Sussex, UK) or a combinations 
with HBX19818 commenced four days post-Mec1 cell administration. Following sacrifice, 
splenic single cell suspensions labeled with hCD45-FITC (Thermo Fisher Scientific) were 
quantified using an Accuri C6 flow cytometer. In some cases, CountBright beads (Thermo 
Fisher Scientific) were used to obtain absolute cell counts. 
 
Cytotoxicity assays, Immunocytochemistry, transfection, HRR and comet assay 
These procedures are described in supplemental data. 
 
Statistical analysis 
Statistical analysis was performed using SigmaPlot 12.5 software (Systat Software Inc, 
London, UK). P≤.05 was considered significant. Data are presented as mean ± SEM 
(standard error of the mean). 
 
Results 
Primary CLL cells overexpress USP7 and demonstrate differential sensitivity to USP7 
inhibition in vitro and in vivo 
To address the feasibility of targeting USP7 in CLL, we assessed the level of USP7 protein 
expression in CLL cells from a patient cohort compared to PBMCs obtained from healthy 
donors. The panel of analyzed CLL samples (n=64) comprised ATM/p53-proficient (n=54) 
and ATM/p53-defective cases (n=5 each). USP7 protein expression was significantly higher 
(P<.0005) in CLL samples (n=64) irrespective of ATM or p53 defects in comparison to 
PBMCs from healthy donors (n=4) (Figure 1A-B). 
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Next, we utilized an irreversible USP7 inhibitor, HBX19818, to investigate the effect of USP7 
inhibition on CLL.33 In CLL cells pre-treated with HBX19818 we observed a dose-dependent 
reduction in the binding of HA-labeled ubiquitin to USP7, but not to USP3, a closely related 
DUB (supplemental Figure S1A). Furthermore, in accordance with the role of USP7 in the 
regulation of protein ubiquitylation, a time-dependent accumulation of poly-ubiquitylated 
proteins was observed following treatment of Mec1 CLL cells with HBX19818 (supplemental 
Figure S1B). Together these results demonstrate that HBX19818 specifically interacts with 
USP7 and functions as an inhibitor of protein de-ubiquitylation. 
In vitro, quiescent CLL cells from patient samples (n=33, including 3 ATM-defective, 3 p53-
defective and 3 ibrutinib-resistant cases) were significantly more sensitive to HBX19818 than 
healthy donor PBMCs (n=4), with EC50 of 6µM vs 21µM, respectively (Figure 1C-D). 
Likewise, primary CLL samples (n=19) induced to proliferate by co-culturing with CD40L/IL-
21 were significantly more sensitive to HBX19818 than healthy donor B cells induced to 
proliferate by the same method (Figure 1E) and the HBX19818 dose (≤10M) used for all 
subsequent experiments was cytotoxic to CLL but not healthy donor lymphocytes. This 
indicated that inhibition of USP7 selectively targets quiescent and proliferating CLL cells 
irrespective of their subtype. Notably, the HBX19818 EC50 of ATM- or p53-defective samples 
(n=6), whether quiescent or proliferating, did not differ significantly from ATM/p53-proficient 
samples suggesting that the cytotoxic effect of HBX19818 occurred through an ATM/p53-
independent mechanism (Figure 1C-E). This finding was corroborated by data on the CII 
(p53-wild-type) and Mec1 (p53-defective) CLL cell lines stably expressing GFPshRNA or 
ATMshRNA,15 which shows that the ATM and p53 functional status of the cell lines did not 
influence sensitivity to HBX19818 (supplemental Figure S1C). 
To examine the anti-tumor activity of HBX19818 in vivo, a Mec1 CLL murine xenograft 
model was employed. Therapeutic doses of HBX19818 were well tolerated in mice. 
Moreover, a 2-week course of bi-weekly treatment led to tumor load reduction as evidenced 
by significant reduction of splenic weight accompanied by decreased splenic engraftment 
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(Figure 1F-G). In addition, siRNA-mediated downregulation of USP7 (supplemental Figure 
S1D) prior to xenotransplantation led to a similar splenic Mec1 tumor load reduction (Figure 
1H). Taken together, the in vitro and in vivo data suggests that USP7 is a promising target in 
CLL and its inhibition with HBX19818 has substantial ATM/p53-independent activity. 
Finally, protein level observations provided additional support for a p53-independent 
mechanism underlying the activity of HBX19818 in CLL. As expected from previous reports, 
treatment of ATM/p53 wild-type CLL cells with HBX19818 induced the upregulation of p53 
(Figure 1I). However, unlike IR, inhibition of USP7 did not induce phosphorylation of p53 
suggesting that the accumulated p53 was not activated. 
 
USP7 inhibition compromises HRR and results in accumulation of DNA damage 
To explore the mechanisms underlying the p53-independent effects of USP7 inhibition, we 
first addressed whether USP7 inhibition leads to differential accumulation of unrepaired DNA 
damage in primary CLLs compared to healthy donor lymphocytes. We performed comet 
assays which utilize the increased electrophoretic mobility of fragmented DNA as a measure 
of DNA damage34 and we also assessed levels of H2AX, a marker of DNA damage. 
Inhibition of USP7 led to increased tail moment and elevated H2AX levels in lymphocytes 
derived from CLL patients or healthy donors (Figure 2A). However, both basal and USP7 
inhibition-induced DNA damage were differentially higher in CLL cells (Figure 2A-B). In 
agreement with this observation, siRNA-mediated depletion of USP7 in HeLa cells also 
increased comet tail moments (supplemental Figure S2). 
We proceeded to investigate the nature of the DNA damage induced by USP7 inhibition. A 
marker of DNA DSBs, 53BP1 foci, accumulated in Mec1 cells after HBX19818 treatment 
both in vitro and in vivo (Figure 2C-D). Moreover, in keeping with our recent report 
demonstrating that USP7 activity is required to stabilize RAD18,29 RAD18 protein levels 
were reduced in both CLL and healthy donor cells following HBX19818 treatment (Figure 
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3A). The impact of USP7 inhibition on RAD18 stability was independent of ATM/p53, as 
evidenced by comparable RAD18 downregulation exhibited by p53 wild-type and defective 
isogenic CLL cell lines stably expressing either GFP (control) or ATM shRNA, when treated 
with HBX19818. RAD18 was also destabilized in HeLa cells following siRNA-induced USP7 
depletion (Figure 3B). The specificity of this effect was demonstrated by the co-expression of 
siRNA-resistant FLAG-USP7 (R-USP7) which replaced the depleted endogenous USP7 and 
rescued RAD18 stability (Figure 3B). 
RAD18 stimulates the repair of DSBs by facilitating the relocalization of proteins required for 
HRR including FANCD2 and RAD51 to sites of DNA damage. Therefore, we examined the 
effect of USP7 depletion or inhibition on HRR by quantifying the formation of IR-induced 
RAD51/FANCD2 foci. Consistent with its importance in promoting HRR, inhibition of USP7 
significantly reduced the formation of IR-induced RAD51 foci in proliferating healthy donor, 
primary CLL and Mec1 cells (Figure 3C,E-G). This difference was observed as early as 1 
hour post-irradiation and is therefore unlikely to be due to cell cycle alterations 
(supplemental Figure S3A). Defective localization Rad51 of was also seen in IR-treated 
HeLa cells depleted of USP7 (Figure 3D,H) and in USP7-/- HCT116 cells (supplemental 
Figure S3B). Furthermore, re-expression of USP7 rescued RAD51 foci in USP7-/- HCT116 
cells (supplemental Figure S3C). In addition to IR, we examined the effect of USP7 
knockdown on HRR induced by mitomycin C (MMC), an alkylating agent that causes DNA 
cross-links necessitating functional HRR for repair. Activation of HRR stimulates the 
ubiquitylation of FANCD2. In accordance with its role in HRR, knockdown of USP7 
decreased FANCD2 ubiquitylation as evidenced by the reduced ratio of ubiquitylated to non-
ubiquitylation-FANCD2 protein, as well as the formation of FANCD2 and RAD51 foci in HeLa 
cells treated with MMC for 24hrs (supplemental Figure S3D-G). 
Lastly, to assess the functional consequences of reduced RAD51 recruitment to sites of 
DNA damage following abrogation of USP7, we utilized the plasmid-based DR-GFP HRR 
reporter system to directly measure HRR. In this assay, restriction enzyme (I-Sce1) directed 
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cutting/DSB formation in a defective GFP gene induces HRR using homologous sequences 
from another differentially defective GFP gene resulting in restoration of GFP function and 
the appearance of fluorescently labeled cells.35 Depletion of USP7 significantly reduced the 
number of GFP-positive cells indicating decreased HRR-dependent DSB repair (Figure 3I 
and supplemental Figure S3H). 
 
USP7 inhibition induces caspase-independent cell death through over-activation of 
PARP1 
We further investigated the process through which tumor cell death occurs when USP7 is 
inhibited. Consistent with a p53-independent mechanism of cellular death, inhibition of USP7 
did not induce caspase-3 or PARP1 cleavage in either quiescent or proliferating primary CLL 
cells. Rather, following exposure of CLL cells to HBX19818 both PARP1 expression and 
activity increased as measured by the level of protein poly ADP-ribosylation (PARylation) 
(Figure 4A). 
PARP1 functions as a DNA damage sensor that catalyzes postranslational modification of 
DNA bound proteins. This is mediated through the formation of poly-ADP ribose (PAR) 
chains that serve as docking platforms for DNA repair factors.36 Over-activation of PARP1 
promotes cell death in two ways.36 Firstly, PAR can migrate across the cytosol from the 
nucleus to stimulate a reciprocal translocation of apoptosis inducing factor (tAIF) from the 
mitochondria to the nucleus to stimulate large scale DNA fragmentation.37 Secondly, 
nicotinamide adenine dinucleotide (NAD+) is the substrate required for the generation of 
ADP-ribose by PARP1. Consequently, over-activation of PARP1 decreases NAD+ levels 
resulting in depletion of ATP and necrotic cell death. We observed evidence for both of these 
cytotoxic mechanisms with HBX19818 treatment. Immunoblotting of isolated nuclear 
fractions showed that HBX19818 was capable of inducing tAIF (Figure 4B). In addition, 
morphological features of dying CLL cells were consistent with necrosis (Figure 4C). This 
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form of cell death may cause inflammation. However, there was no evidence of systemic 
inflammation in HBX19818-treated animals (supplemental Figure S3I). Finally, the 
antagonistic action of PARP inhibition with HBX19818, provided further evidence for the role 
of PARP1 in this process (Figure 4D). Thus, the aberrant accumulation of DSBs upon USP7 
inhibition leads to protein hyper-PARylation and ATM/p53 independent cell death. 
 
USP7 inhibition sensitizes ATM/p53-defective CLL cells to HRR inducing 
chemotherapy 
Given the role of USP7 in HRR, we hypothesized that targeting USP7 would enhance the 
efficacy of HRR-inducing chemotherapeutic agents such as cyclophosphamide and MMC. 
Therefore, we assessed the effect of combining HBX19818 with physiologically relevant 
concentrations of these agents.38,39 
In Mec1 cells, the addition of HBX19818 led to potentiation of H2AX induced either by MMC 
or the metabolically active form of cyclophosphamide, 4HC (Figure 5A). Accordingly, the 
combination of HBX19818 with either 4HC or MMC exacerbated the cytotoxicity of either 
agent in Mec1 cells and p53-defective (Figure 5B-C,E-F) primary CLL cells (supplemental 
Figure S4A-B). Calculation of the combination index (CI) showed that in vitro co-treatment 
with HBX19818 and chemotherapeutics was synergistic in p53-deficient cells (Figure 5D,G). 
We observed no synergy between 4HC or MMC and HBX19818 in p53 wild type CLL 
(supplemental Figure S4A-B), consistent with a high efficacy of DNA damaging agents in 
cells with an intact p53 apoptotic pathway.   
Subsequently, we used the Mec1 xenograft model to examine the in vivo efficacy of 
combining two doses of the USP7 inhibitor with cyclophosphamide or a non-DNA damaging 
agent, the CD20 antibody, rituximab. Whilst we observed that HBX19818, 
cyclophosphamide or rituximab as monotherapies exhibited anti-tumour activity, only the 
combination of cyclophosphamide with the higher dose of HBX19818 had a more potent 
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effect than cyclophosphamide alone or the combination of HBX19818 with rituximab (Figure 
5H).  Based on this, it would appear that USP7 inhibitors are more effective when used in 
combination with a DNA damaging agent, thus supporting the in vitro findings. 
The effect of the HBX19818-chemotherapy combination was investigated further in HeLa 
cells. Similar to the effect of USP7 inhibition on CLL cells, HeLa cells showed reduced 
viability when exposed to HBX19818 (supplemental Figure S4C) or when USP7 was 
depleted (supplemental Figure S4D). Pharmacological inhibition (8µM HBX19818; 
supplemental Figure S4E-F) or siRNA downregulation of USP7 (supplemental Figure S4G-
H) significantly increased the sensitivity of HeLa cells to MMC and 4HC. USP7 depletion 
also increased the sensitivity of HeLa cells to MMC as assessed by colony formation assay 
(supplemental Figure S4I). Furthermore, the sensitivity of HeLa cells to MMC was increased 
by an alternative USP7 inhibitor, HBX41108 (supplemental Figure S4J). Taken together, 
these results substantiate the potentiating effect of USP7 inhibition on HRR-inducing 
chemotherapy. 
 
Discussion 
The treatment of hematological malignancies with DDR defects remains an unmet clinical 
need. In CLL, the addition of monoclonal antibodies to chemotherapeutic agents represents 
a therapeutic advance, with deep, sustained responses achievable in a substantial 
proportion of patients that are often translated into long-term treatment-free survival.40,41 
Nonetheless, monoclonal antibodies have failed to overcome chemoresistance in DDR-
defective CLL, particularly in patients with del(17p) and/or TP53 mutation.42,43 Although BCR 
signaling inhibitors and Bcl-2 inhibitors have proven efficacy against DDR-defective CLL, 
deep remissions are infrequent with BCR signaling inhibitors, and prolonged treatment with 
these agents is required.7-10 The presence of residual disease provides a reservoir for 
eventual disease relapse, especially in ATM/p53-defective CLL with high levels of genomic 
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instability.44-46 Indeed, emerging evidence suggests that therapies eliciting deep remissions 
may provide enhanced benefit for del(17p) or del(11q) CLL.47 Moreover, only a proportion of 
CLL patients relapsing from BCR signaling inhibitors respond to alternative kinase inhibitors, 
highlighting the need for novel therapeutic approaches.48,49 
In this study, we demonstrate that USP7 represents a new therapeutic target for CLL. 
Treatment with USP7 inhibitor, either alone or in combination with chemotherapy, led to the 
potent killing of CLL cells in vitro and in vivo independently of ATM and p53 function. Even 
when primary CLL cells were co-cultured with CD40L/IL-21 they were still highly responsive 
to USP7 inhibition, suggesting that such an approach could overcome pro-survival 
microenvironmental signals. In addition, we show for the first time that this cytotoxic effect is 
mediated, in part, through the suppression of HRR upon USP7 inhibition, allowing 
accumulation of unrepaired DSBs and the induction of p53-independent cell death. 
We show that CLL tumour cells exhibit a basal level of genome instability and as a 
consequence they are likely to have a higher dependence on the activity of USP7 than 
healthy donor lymphocytes. We also demonstrate that, when USP7 is inhibited, the relative 
increase in DNA damage accumulation is higher in the CLL cells. Whilst the underlying 
mechanism for the differential sensitivity of CLL cells to the USP7 inhibitor is unclear, we 
speculate that this most likely arises through synthetic lethality in which the HR-defect (and 
other DNA repair deficiencies e.g. post-replication repair) caused by inhibiting USP7 
interacts with CLL specific abnormalities in back-up DNA repair pathways, such that genetic 
damage is induced to intolerable levels and cell death is triggered. 
Previous studies of USP7 in myeloma and solid malignancies, including prostate, 
hepatocellular and ovarian cancers, and glioma revealed that it is frequently overexpressed 
in tumors and its overexpression is associated with a worse prognosis.22,50-53 This suggests 
that USP7 may function as an oncogene and that aberrant USP7 expression may contribute 
to tumorigenesis. Consistent with this, overexpression of USP7 in hepatocellular carcinoma 
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cells increased tumor cell growth in vitro and in vivo.51,52 In this study, we observed high 
levels of USP7 expression in primary CLL samples suggesting that USP7 deregulation could 
also contribute to the pathogenesis of lymphoid malignancies. 
The anti-myeloma activity of USP7 inhibition with the inhibitor P5091 has been shown to 
occur through activation of the MDM2-p53 axis.22 Here, we identified a novel mechanism 
whereby USP7 inhibition initiates p53-independent killing of malignant cells (Figure 6). Our 
data suggests that the accumulation of DNA damage in CLL cells stimulates the production 
of PAR through the over-activation of PARP1. This results in necrotic death, most probably 
due to the depletion of ATP.54 We also observed that, in a proportion of CLL cases, PAR-
stimulated nuclear translocation of AIF occurs in response to USP7 inhibition. This in turn 
can induce DNA fragmentation as previously reported.36,55 It has been demonstrated that the 
USP7 inhibitor P5019 also inhibits USP47 with a comparable EC50 to USP7.
56 Whilst the 
potential off-targets effects of HBX19818 have not been thoroughly tested in this study we 
have demonstrated that many of the cellular phenotypes resulting from USP7 inhibition with 
HBX19818 can be recapitulated by knocking down USP7 with siRNA. Therefore, whilst we 
cannot completely rule out the possibility that some of the anti-tumour activity we have 
observed with the USP7 inhibitor HBX19818 are not due to off-target effects, we are 
confident that the predominant effect is mediated by inhibiting USP7. 
Our recent study identified RAD18 as a novel substrate for deubiquitylation by USP7.29 
RAD18 is known to protect stressed replication forks from collapse by coordinating three 
DDR pathways, namely, DNA inter-strand cross-link repair, DNA damage tolerance and 
HRR.57-60 In keeping with this, we showed that disruption of USP7 in epithelial, healthy donor 
lymphocytes or malignant lymphoid cells led to reduced RAD18 stability and failure to form 
DNA damage-induced RAD51 and FANCD2 foci. Therefore, we propose that replication fork 
instability caused by USP7 inhibition coupled with a loss of RAD18-dependent replication 
fork protection and repair mechanisms allows damaged forks to collapse into DSBs, the 
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accumulation of which leads to tumor cell death. Consistent with this, CLL cells treated with 
HBX19818 exhibit increased 53BP1 foci formation, which is indicative of unrepaired DSBs.61 
Although we focused our analysis on the HRR pathway, there is evidence to suggest that 
other DNA repair pathways might be affected by USP7 inhibition. Firstly, non-cycling CLL 
cells, in which HRR is inactive, still exhibit sensitivity to USP7 inhibition. Secondly, we 
observed marked synergism in non-cycling CLL cells when USP7 inhibition was combined 
with 4HC (A.A. and E.S., unpublished data, May 14 2014). Whilst DNA alkylation induced by 
cyclophosphamide will produce HRR-responsive DSBs in S-phase, it is most likely that this 
type of DNA damage is repaired through the concerted actions of the base excision, 
nucleotide excision and mismatch repair pathways in non-cycling cells.62 As such, the repair 
of cyclophosphamide-induced DNA damage requires the actions of multiple independent 
DNA repair pathways. Therefore, in addition to HRR, USP7 inhibition could also suppress 
one or more of these pathways. These mechanisms could be explored in future studies. The 
activity of USP7 inhibition on quiescent cells is of clinical significance, given that the CLL 
population in peripheral circulation is mostly quiescent. The combined effect of USP7 
inhibition on both the proliferating and quiescent populations could enhance CLL eradication. 
As such, our findings have important clinical implications. Regardless of the primary type of 
DNA damage inflicted, many chemotherapeutic agents induce DSBs that require HRR for 
their resolution and cell survival.63 Consequently, the suppression of HRR by USP7 inhibition 
could sensitize tumor cells to HRR-inducing chemotherapeutic agents. Indeed, we showed 
that HBX19818 was highly synergistic when used in combination with cyclophosphamide or 
MMC. Thus, combination with USP7 inhibitor could potentially allow lower doses of 
chemotherapeutic agents to be administered to frailer CLL patients. In the context of 
ATM/p53-defective CLL, the ability of USP7 inhibition to re-sensitize chemoresistant cells to 
chemotherapeutic agents supports the clinical investigation of the USP7 inhibitor-
chemotherapy combination for the treatment of these tumors. Indeed, the potent in vitro 
cytotoxic effect of such therapeutic combinations suggests that they might produce deep and 
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durable clinical response. Furthermore, the p53-independent tumor cell killing by USP7 
inhibition suggests that such a strategy might be useful for other hematological malignancies 
with ATM/p53 defects.64-68  
In summary, we have provided evidence for a new p53-independent role of USP7 in 
regulating DNA DSB repair. In addition, we have demonstrated the pre-clinical efficacy of 
USP7 inhibition in CLL both as a single agent and in combination with chemotherapy. 
Collectively, our in vitro and in vivo data suggests that USP7 is a promising therapeutic 
target and supports progression of USP7 inhibitors into clinical studies for the treatment of 
chemorefractory CLL. 
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Figure legends 
Figure 1. USP7 is overexpressed in CLL and can be targeted with HBX19818 without 
activating p53 phosphorylation. (A) Immunoblotting and (B) densitometry quantification of 
primary CLL and healthy donor PBMCs demonstrates overexpression of USP7 in CLL 
samples. USP7 expression was normalized to β-Actin. (C) HBX19818 dose responses of 
quiescent primary CLL cells and healthy donor PBMCs and the resultant EC50 for (D) 
quiescent and (E) proliferating healthy donor and primary CLL cells following 72h treatment. 
HBX19818 treatment of a chemoresistant Mec1 CLL xenograft model led to (F) reduction of 
splenic weight and (G) splenic tumor engraftment. (H) Xenotransplantation of confirmed 
USP7 knock-down Mec1 cells by siRNA transfection also led to reduced splenic 
engraftment. (I) In a panel of 5 wild-type CLLs, 6h HBX19818 treatment stabilized p53 but 
did not induce its phosphorylation. As a positive control for p53 phosphorylation, CLL9 & 
CLL57 were treated with 5Gy IR. Data were compared using a two-tailed Student’s t-test and 
statistical significance denoted by: *P≤.05, ***P≤.001. 
 
Figure 2. Inhibition of USP7 with HBX19818 induces accumulation of DNA damage. (A) 
DNA damage was significantly elevated both in primary CLL cells (n=3) and healthy donor 
lymphocytes (n=3) treated with 8µM HBX19818 for 6h, as quantified from Comet assay 
derived tail moments. HBX-induced DNA damage was increased 3.92-fold in CLL cells and 
2.42-fold in healthy donor cells, relative to DMSO. Representative images of DMSO and 
HBX19818 treated cells are depicted. (B) Levels of the DNA damage marker, H2AX, 
increased following HBX19818 treatment of quiescent and proliferating primary CLL cells, 
and proliferating healthy donor cells. Lamin B1 (LMNB1) was the loading control. 
Immunofluorescence labelling showed significant induction of 53BP1 foci, a DSB marker, in 
Mec1 cells following 6h treatment with HBX19818 (C) in vitro and (D) in vivo, in the 
chemoresistant murine xenograft model. Representative images shown (DAPI: blue; 53BP1: 
green) and the mean data from three independent experiments is presented. Original 
AGATHANGGELOU et al USP7 INHIBITION TARGETS ATM AND P53 MUTANT CLL 
24 
 
magnification ×60 for panels A,C,D. Data were compared using a two-tailed Student’s t-test 
and statistical significance denoted by: *P≤.05. 
 
Figure 3. USP7-disrupted cells show reduced activation of HRR. (A) Normal healthy 
donor PBMCs and three isogenic CLL cell lines (two p53-wild type (wt) and one p53-
defective) expressing the indicated shRNAs show diminished expression and thus 
destabilization of RAD18 protein following treatment with HBX19818. β-Actin was the 
loading control. (B) HeLa cells transfected with USP7 or control (Con) siRNAs and empty 
(Vec) or siRNA-resistant Flag-USP7 (R-USP7) expressing plasmid vectors, demonstrate 
rescue of RAD18 stability in a complementation assay. The reduction of RAD18 levels in the 
presence of USP7 siRNA alone is prevented by the expression of R-USP7 which replaced 
the endogenous USP7 depleted by USP7 siRNA. Ub denotes ubiquitylated. (C,D) 
Representative immunofluorescence labeling of DNA damage markers, H2AX and RAD51 
(green) with DAPI counterstained nuclei (blue) and (E-H) quantification of RAD51 foci 
formation from 24h time-course studies of 5Gy IR-induced damage (n=3). (C,G) In MEC1 
cells, (E) normal healthy donor cells and (F) primary CLL cells, HBX19818 induced inhibition 
of USP7 1h prior to irradiation abrogated the formation of IR-induced RAD51 foci. (H) IR-
induced RAD51 foci formation was reduced in HeLa cells following USP7-depletion by USP7 
siRNA. (I) Analysis of HRR using the DR-GFP reporter assay in U2OS cells showed that 
HRR is compromised by USP7 depletion. CtIP depletion was the positive control for HRR-
defective cells. Original magnification ×60 for panels C,D. Data were compared using a two-
tailed Student’s t-test and statistical significance denoted by: *P≤.05, **P≤.01. 
 
Figure 4. USP7-inhibitor HBX19818 increased PARP1, protein PARylation and nuclear 
AIF. (A) HBX19818 treatment (6h) elevates PARP1 and PARylated protein levels in the 
absence of caspase-3 cleavage (cl-CASP3) in both quiescent (without CD40L/IL21) and 
proliferating (with CD40L/IL21) primary CLL cells. CD40L/IL21-stimulated proliferation was 
confirmed by the presence of cyclin A expression. SMC1 was the loading control. (B) 
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Analysis of nuclear extracts from proliferating primary CLL cells demonstrated that 
HBX19818 induced tAIF accumulation in the nucleus. (C) HBX19818 treatment for 72h 
induced CLL cells to swell and disperse their contents (arrows), morphological changes that 
are consistent with necrotic cell death. (D) In ATM/p53-defective primary CLL induced to 
proliferate (n=6) the PARP inhibitor talazoparib did not potentiate the cytotoxic activity (left 
panel) of HBX19818 and acted in an antagonistic manner as indicated by combination 
indices (right panel). 
 
Figure 5. Inhibition of USP7 sensitized CLL cells to DNA cross-linking agents. (A) 
HBX19818 potentiated the induction of H2AX in Mec1 cells treated with either MMC or 4HC 
for 72h. -Actin was the loading control. HBX19818 (8µM) significantly (P<.05) increased the 
sensitivity of (B,E) Mec1 cells (n=3) and (C,F) proliferating p53-defective primary CLL cells 
(n=3) to either (B,C) 4HC or (E,F) MMC. Inserts indicate the activity of HBX19818 alone. The 
accompanying combination index-plots indicate synergism of HBX19818 with (D) 4HC and 
(G) MMC, in both Mec1 and p53-defective primary CLL cells. (H) Tumor load was reduced 
by all treatment regimes, both single agents [(5 and 10mg/kg HBX19818, 20mg/kg 
cyclophosphamide (CycloP), 0.5mg/kg rituximab (RTX)] and combinations with HBX1918 vs 
control (DMSO) treatment. Tumor load reduction induced by cyclophosphamide (20mg/kg; 
n=4) alone was significantly enhanced when co-administered with the higher dose of 
HBX19818 (10mg/kg; n=4). This demonstrated that HBX19818 increased the in vivo efficacy 
of cyclophosphamide in the Mec1 murine xenograft model. Data were compared using two-
way ANOVA (B,C,E,F,) or two-tailed Student’s t-test (H) and statistical significance denoted 
by: *P≤.05, **P≤.01, ***P≤.001. 
 
Figure 6. A model for the effect of USP7 inhibition on DDR. The sequence of events 
inferred from the results in this study is presented in black. Other consequences of USP7 
inhibition upon DDR, inferred from other studies, are in grey. 
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